Catalyst Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Catalyst Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Catalyst is a well-executed rare disease specialist with proven commercial capabilities, strong financials, and a clear 2026 guidance outlook ($615M-$645M revenue), supported by expanding patient access and lifecycle management opportunities.
What is Catalyst Pharmaceuticals, Inc.'s industry? Catalyst Pharmaceuticals, Inc. (catalystpharma.com) operates in Specialty Pharmaceuticals / Rare Diseases. AskCyborg classifies Catalyst Pharmaceuticals, Inc. under Specialty Pharmaceuticals / Rare Diseases in its company registry.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare diseases, particularly neuromuscular and neurological disorders. The company achiev...
Cyborg Score thesis
Catalyst is a well-executed rare disease specialist with proven commercial capabilities, strong financials, and a clear 2026...
Read the full analyst-debate transcript →Get the Latest Catalyst Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCatalyst Pharmaceuticals, Inc. Overview
Pro stress-test →Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare diseases, particularly neuromuscular and neurological disorders. The company achieved record revenue of $589 million in 2025, growing 19.8% year-over-year, with a robust product portfolio anchored by three marketed drugs addressing unmet patient needs in orphan disease segments.
Strategic Profile
Pro stress-test →Catalyst's strategy centers on in-licensing proven therapies and expanding their market penetration through commercial execution and lifecycle management. The company markets FIRDAPSE (amifampridine) for Lambert-Eaton Myasthenic Syndrome, AGAMREE (vamorolone) for Duchenne Muscular Dystrophy, and FYCOMPA (perampanel) for epilepsy. With strong cash position ($709M) and disciplined business development, the company is positioned for continued organic growth while selectively pursuing development-stage acquisitions with established proof of concept.
Competitive Landscape
Pro stress-test →Catalyst competes in the rare disease pharmaceutical market against larger diversified pharma companies and specialized rare disease biotech firms. Key competitive advantages include established commercial infrastructure, proven ability to successfully launch and scale rare disease products, and orphan drug exclusivity protections. Main competitive threats include potential generic entry for FIRDAPSE (Lupin licensed to commercialize generic beginning February 2035) and competing therapies in overlapping disease areas.
Industry Context
Catalyst Pharmaceuticals, Inc. operates in Specialty Pharmaceuticals / Rare Diseases.
Key facts
Founded: 2002 · Headquarters: Coral Gables, Florida, US · Revenue: $589M (2025)